Chinese Health Care Company Still Growing Strong
Chinese stock markets may be tumbling, but the country’s largest preventive healthcare services company, iKang Healthcare Group (NASDAQ: KANG), is growing strong. Last week it announced its sixth acquisition of the year, this time for three medical centers in three major cities in Shandong province. The targets were three franchises of a rival private preventive services provider, Ciming Checkup Group. iKang was happy to boast this is its third acquisition this year of former Ciming franchises. Financial terms were not disclosed for any of the transactions. Read More »InSite Vision Sees a Better Offer
Back in June, InSite Vision Inc. (OTCBB: INSV), which focuses on specialty ophthalmic products for diseases of the eye, agreed to be acquired by QLT Inc. (NASDAQ: QLTI) in an all-stock transaction. QLT shareholders would own about 89% of the combined company, which would retain the QLT name and be incorporated in Canada, thanks to QLT’s base in Vancouver, British Columbia. Last week, however, InSite informed QLT that a “multi-national pharmaceutical company” had made an unsolicited bid of $0.25 per share of INSV, which the target decided was a better offer than QLT made. QLT now has to match the proposed price, or terminate the agreement. Our bets are on Valeant Pharmaceuticals (NYSE:... Read More »Universal Health Ups its UK Holdings
The United Kingdom is still luring behavioral health buyers from the United States. Last week Universal Health Services (NYSE: UHS) picked up Alpha Hospitals Holdings Ltd., a privately held company, for an undisclosed price. Alpha operates four behavioral health hospitals with a combined total of 305 beds. It will be added to Universal’s London-based Cygnet Health Care group, which was acquired in September 2014 for $335 million. Cygnet came with 17 facilities, including 15 inpatient behavioral health hospitals (743 beds, total) and two nursing homes. Astute readers will recall that U.S. rival Acadia Healthcare Company (NASDAQ: ACHC) picked up The Manor Clinic, a 15-bed residential rehab... Read More »Biotech M&A in 2015
Last Friday, the Biotech sector, represented by the Nasdaq Biotechnology index (NASDAQ: IBB), officially entered a correction phase, based on a 14% drop in valuations since July 20. That could put a damper on a sector that’s seen tremendous M&A activity in 2015, with 117 deals announced so far (vs. 136 total in 2014), and nearly $40 billion in spending (well up from the $21 billion spent in 2014). While the AbbVie’s (NYSE: ABBV) $21 billion takeover of Pharmacyclics (NASDAQ: PCYC) has a lot to do with the large total, billion-dollar deals haven’t been uncommon. Take a look. TargetAcquirerPrice PharmacyclicsAbbVie$21.0 billion NPS PharmaceuticalsShire plc$5.2 billion... Read More »Schedule a demo
Gain access to the best healthcare and long-term care investment intelligence, data, and analysis.
